What did Hengrui, Huahai, Qilu, Beida and Yangtze River boss say? Innovative R & D, volume purchasing, consistency evaluation

On March 5, the second session of the 13th National People's Congress was opening in Beijing The owners and representatives of all enterprises made their voices through different channels They expressed their views and made suggestions on innovation and R & D, volume purchase, generic drug consistency evaluation, Chinese medicine development, etc Sun piaoyang, chairman of Hengrui pharmaceutical, said that he focused on generic drugs and innovative drug research and development He believes: first, the implementation effect of China's generic drug policy is of great significance to the protection of national health China's generic drug policy should continue to advance steadily to ensure that the quality of generic drugs is reliable, the price is reasonable and the supply is sufficient Specifically, the state should set the payment price of medical insurance, and the market needs free competition Support private enterprises and brand imitation, and encourage generic drugs to go out and participate in international market competition 2、 At present, China's pharmaceutical innovation has the characteristics of high investment, high risk and long cycle, but whether it can achieve high return is still worth observing Therefore, the state should first continue to support the research and development of innovative drugs in terms of policies, and then the drug review rules should be more in line with the development laws of innovative drugs; and actively introduce medical insurance and strengthen the effective protection and encouragement of intellectual property rights Ding lieming of Beida Pharmaceutical Co., Ltd.: it is suggested to compensate for the patent period of patent innovative drugs first listed in China Ding liming, chairman of Beida Pharmaceutical Co., Ltd., proposed to implement patent period compensation for patent innovative drugs listed in China for the first time, with a maximum compensation period of no more than 5 years; authorized the State Council to formulate measures for the administration of patent period compensation for drugs, and defined the scope of compensation, application conditions, time limit calculation methods, application procedures and materials, patent protection scope within the compensation period, etc At the same time, it is also suggested to give priority to domestic innovative drugs in volume procurement Li Yan, President of Qilu Pharmaceutical Group, put forward five suggestions on integrating the evaluation of clinical research development ability into the evaluation of medical institutions 1、 We will increase the investment in clinical research management funds and personnel, establish independent and full-time clinical research management departments, and carry out the management of clinical research affairs 2、 The number of clinical studies initiated by researchers and the evaluation of research output are included in the rating of medical institutions 3、 We should strengthen the hierarchical management of the ethics committee, and take the review ability and efficiency of the ethics committee as one of the evaluation indicators of the medical institutions' level review 4、 Improve the scientific research design level and scientific research literacy of clinical medical personnel 5、 Encourage medical staff to actively carry out and participate in all kinds of clinical research, further improve the innovation environment of medical staff, and encourage clinicians to carry out and participate in technical innovation activities of medical devices based on practical experience Li Jie: strengthen the implementation of the centralized purchase policy of hospital drugs Li Jie, chairman of humanwell pharmaceutical, said that to strengthen the implementation of the centralized purchase policy of hospital drugs, relevant government departments should fully implement the spirit of documents, strengthen the supervision and management of the whole process, and require the production enterprises to actively fulfill their own responsibilities, but also actively protect their vital interests to be truly implemented Ding Zhao, chairman and President of Sichuan Huiyu Pharmaceutical Co., Ltd put forward four suggestions on centralized procurement: it is suggested to learn from the mature centralized procurement practices in the UK; it is suggested to convert the centralized procurement varieties and specifications into the minimum unit; it is suggested that more varieties should be included in the centralized procurement as soon as possible; it is suggested that supporting policies should be implemented as soon as possible Consistency evaluation: Chen Baohua, chairman of Huahai pharmaceutical, proposed to further deepen the reform of the medical and health system and promote the high-quality and healthy development of the pharmaceutical industry Accelerate the promotion of generic drug consistency evaluation; improve the hospital access mechanism of drugs through consistency evaluation; improve the mechanism of drug production process change to ensure that new technologies and equipment play an active role in improving drug quality and environmental protection Xu Jingren, Yangzijiang pharmaceutical: consistency evaluation of generic drugs is the threshold for pharmaceutical enterprises to compete Xu Jingren, chairman of Yangzijiang pharmaceutical, said that the future market opportunities and challenges of Yangzijiang pharmaceutical co-exist, strictly control the quality of generic drugs, ensure the quality of products with zero defects, give priority to the production of varieties that have been selected and collected in the consistency evaluation, ensure the supply of products, and report the inventory data of the selected varieties on time according to the requirements of joint procurement He believed that the future competition in the generic pharmaceutical market, Consistency evaluation is the entry threshold, and the price of products is the key to success or failure Hao Yunjie, dongyangguang: consistency evaluation brings huge capital pressure Please encourage more Hao Yunjie, the quality director of Dong sunshine, suggests to encourage the secondary technology development of API enterprises in view of the huge capital pressure brought by the drug consistency evaluation For enterprises that achieve large-scale production through technological innovation and product quality reaching the international advanced standards, they can pass the achievement appraisal and give a certain reward For the products planned for the quality consistency evaluation of generic drugs, they can apply for project approval After the human bioequivalence test is completed and the approval is completed, certain financial subsidies will be given to enterprises in different times; the internationalization of private pharmaceutical enterprises will be encouraged, and enterprises that have passed the certification of developed countries such as Europe, America and Japan and have completed the registration of generic drugs and APIs in these countries will be given certain rewards Development of traditional Chinese medicine: establish a coordination mechanism to promote the development of traditional Chinese Medicine First, establish a coordination mechanism at the level of the State Council Under the framework of "one law, one outline and two plans", put forward the "top-level design of traditional Chinese Medicine Inheritance and development", reasonably allocate the functions of departments involved in the whole industry chain management of traditional Chinese medicine, minimize the regulatory gap and inefficiency brought by "Jiulong water treatment", and improve the coordination and scientificity of supervision Second, we should urge the State Administration of traditional Chinese medicine to perform its statutory duties in charge of the work of traditional Chinese medicine, give it full authorization to carry out relevant work in accordance with the law of traditional Chinese medicine, and establish the "leading group for the development of traditional Chinese medicine under the State Council" if necessary Third, urge the health and Health Commission and the Chinese medicine bureau to truly implement the national policy of "attaching equal importance to both traditional and Western medicine", fully understand the clinical value of traditional Chinese medicine, promote the establishment of clinical pathway of traditional Chinese medicine, strengthen the management of rational use of drugs, and correct the rough treatment of traditional Chinese medicine Fourth, urge the State Food and drug administration to study and formulate the review and approval system of traditional Chinese medicine in line with the characteristics of traditional Chinese medicine as soon as possible, incorporate the formulation of the administrative measures for registration of traditional Chinese medicine into the revision plan, and start the re evaluation work after the listing of traditional Chinese medicine Fifthly, we need to urge the market supervision bureau to take the lead, coordinate the Ministry of agriculture and rural areas, the Ministry of Commerce, the Ministry of natural resources, the Ministry of industry and information technology, the forestry and grassland Bureau, the drug administration, the Chinese medicine bureau, the health and Health Committee and other departments to carry out the work of "rectifying the production, circulation and use of traditional Chinese medicine", form a long-term mechanism, and effectively guarantee the quality, safety and efficacy of traditional Chinese medicine from the source Sixth, March 17 will be designated as the traditional Chinese medicine Festival At the same time, we will strengthen the publicity and promotion of traditional Chinese medicine culture, and enhance the Chinese people's confidence in traditional Chinese medicine culture Only when Chinese medicine goes out of the country can we have the foundation Treasure Island pharmaceutical industry Fang Tonghua: to establish a quality standard system for authentic Chinese herbal medicines in an all-round way, director of treasure island pharmaceutical industry long Tonghua proposed that traditional Chinese herbal medicines are the material basis for the inheritance and development of traditional Chinese medicine Authentic Chinese herbal medicines are the representatives of traditional high-quality Chinese herbal medicines in China Authentic Chinese herbal medicines come from specific production areas and have unique efficacy They need to grow in specific areas to ensure their excellent quality However, at present, the phenomenon of planting traditional Chinese medicine in different places is also prominent Blind introduction in unsuitable planting areas can not guarantee the quality of traditional Chinese medicine Therefore, it is necessary to accelerate the construction of the standard system of genuine Chinese medicine, realize the standardized management from the aspects of planting, processing and circulation of Chinese medicine, and ensure the quality and safety of Chinese medicine Zhao Chao, step Pharma: at the same time of increasing the investment in traditional Chinese medicine, Zhao Chao, President of step Pharma, said that in addition to consolidating and developing modern traditional Chinese medicine, step Pharma should continue to increase the investment in science and technology, quality standards and quality control of traditional Chinese medicine, but also increase the transformation to chemical and biological drugs, and implement the two wheel drive strategy Wu Xiangjun of other Yiling pharmaceutical industry: it is suggested to strengthen the training of general practitioners to make up for the short board of medical and health development Wu Xiangjun, general manager of Yiling pharmaceutical industry in Shijiazhuang, pointed out that the grass-roots medical service is still the short board of medical and health development We should strengthen the training of general practitioners and put forward four suggestions: first, improve the level of education and diagnosis of general practitioners We will further expand the apprenticeship model at the grass-roots level, including the implementation of other theoretical teaching, simulation training, network training, clinical teaching, etc., and cultivate a group of medical talents for the prevention, diagnosis and treatment of common diseases Second, improve the general practitioner's health management service ability Health management is an important part of "healthy China", and will become a major development direction in the future Third, we should strengthen the differentiated medical service ability of general practitioners The current situation, development level and trend of diseases in different regions are different, so it is necessary to strengthen the general practitioners' grasp and judgment of diseases in different regions Fourth, edit and publish more guide books suitable for grass-roots diagnosis and treatment There are some medical guidelines that grassroots doctors still have difficulties in mastering We should increase the books on clinical practice of general practitioners Hua Lan bio health: standardize and integrate the industry and build confidence in domestic vaccines In view of the vaccine situation in China, Ankang, President of Hualan biology, put forward: first, support the expansion and strengthening of China's medical industry while seeing problems and strengthening supervision, and build up the confidence of all sectors of the society in domestic vaccines; second, promote enterprises to strengthen technological innovation while standardizing and integrating the industry; third, further improve the government procurement mechanism, and increase the procurement of some vaccines In order to deal with the outbreak effectively, the government should further introduce emergency plans and measures, and establish a long-term prevention mechanism for key groups and diseases Information source: Sina pharmaceutical, Xinhuanet, China Securities, Zhongjing medical and health capital circle, e-medicine manager, enterprise official website and other statements: this point of view only represents the author, not the position of yaozhinet, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.